Day One Biopharmaceuticals Reports 313.9% Revenue Increase in Q2 2025

Day One Biopharmaceuticals, Inc. reported significant financial results for the second quarter of 2025, showcasing a substantial increase in revenue driven by the commercial launch of its product OJEMDA. The company generated total revenues of $33.9 million for the three months ended June 30, 2025, compared to $8.2 million for the same period in 2024, marking a 313.9% increase. Product revenue alone surged to $33.6 million, a 309.7% rise from the previous year, attributed to increased sales of OJEMDA, which was approved by the FDA in April 2024 for treating pediatric low-grade glioma.

In terms of expenses, Day One Biopharmaceuticals reported total operating expenses of $68.9 million for the second quarter, down 44% from $123 million in the prior year. This reduction was primarily due to a significant decrease in research and development costs, which fell from $92.1 million to $36.1 million, largely because there were no upfront or milestone payments during the quarter, compared to a $55 million payment made in the previous year. The company recorded a net loss of $30.3 million for the quarter, a notable improvement from a net loss of $4.4 million in the same quarter of 2024.

The company’s balance sheet as of June 30, 2025, showed total assets of $519 million, down from $582.8 million at the end of 2024. Current assets decreased to $494.4 million, primarily due to a reduction in cash and cash equivalents, which fell to $35.6 million from $125 million at the end of 2024. The decrease in cash was attributed to net cash used in operating activities of $83.8 million during the first half of 2025, reflecting ongoing investments in research and development and operational expenses.

Strategically, Day One Biopharmaceuticals has made significant moves, including the licensing agreement with Ipsen for the commercialization of tovorafenib outside the U.S., which included an upfront payment of $70.8 million. The company is also eligible for up to $380 million in additional milestone payments and tiered royalties on net sales. Furthermore, the company has expanded its pipeline with the acquisition of DAY301, a novel antibody-drug conjugate, and has initiated clinical trials for this product.

Looking ahead, Day One Biopharmaceuticals anticipates continued growth driven by the commercialization of OJEMDA and the advancement of its clinical pipeline. The company expects to utilize its cash reserves to support ongoing operations and product development through at least the next twelve months. However, it acknowledges the potential need for additional financing to support its long-term growth strategy, which may involve equity offerings or collaborations.